Neurology

Neurona Therapeutics is advancing allogeneic cell therapy for drug-resistant mesial temporal lobe epilepsy (MTLE) with its promising NRTX-1001 therapy. Supported by a $102 million financing round, Neurona is navigating the…

Neurona Therapeutics has secured $102 million to advance its innovative cell therapy for epilepsy into phase 3 testing. The therapy, NRTX-1001, targets drug-resistant mesial temporal lobe epilepsy using GABAergic interneurons…